Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen Inc. is making significant strides in its investment and development pipeline with the recent partnership with Stoke Therapeutics focused on zorevunersen, a promising drug candidate aimed at treating Dravet syndrome, a severe genetic disorder linked to epilepsy and developmental challenges. Under this agreement, Biogen will pay an upfront fee...

Biogen Partners with Stoke Therapeutics to Develop Zorevunersen for Dravet Syndrome, Investing Up to $550 Million